View Older Stories View More Recent Stories

Feb 27, 2024 07:00AM Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
Feb 27, 2024 06:45AM Merck to Participate in the TD Cowen 44th Annual Health Care Conference
Feb 23, 2024 06:23AM Merck (MRK) Reports Positive EU CHMP Opinion for KEYTRUDA in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectabl
Feb 23, 2024 06:20AM Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment
Feb 15, 2024 08:45AM Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
Feb 5, 2024 06:33AM Merck Animal Health (MRK) Acquires Elanco’s (ELAN) Aqua Business for $1.3B Cash
Feb 5, 2024 06:33AM Merck Animal Health to Acquire Elanco’s Aqua Business
Feb 1, 2024 06:30AM Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results
Jan 29, 2024 05:54AM Merck's (MRK) KEYTRUDA Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC)
Jan 27, 2024 10:00AM Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephr
Jan 26, 2024 10:00AM Merck (MRK) Reports KEYTRUDA Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothel
Jan 26, 2024 10:00AM Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced
Jan 23, 2024 02:44PM Merck Announces Second-Quarter 2024 Dividend
Jan 19, 2024 06:45AM Merck to Hold Fourth-Quarter and Full-Year 2023 Sales and Earnings Conference Call Feb. 1
Jan 15, 2024 08:15AM Merck Animal Health's Fourth Veterinary Wellbeing Study Indicates Progress in Addressing Mental Health Challenges Among Veterinary Teams
Jan 12, 2024 05:30PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer
Jan 8, 2024 07:34AM Merck (MRK) to Acquire Harpoon Therapeutics (HARP) for $23/sh Cash or $680M
Jan 8, 2024 07:30AM Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline
Jan 5, 2024 06:46AM Merck (MRK) Announces Phase 3 Trial Initiations for Four Investigational Candidates
Jan 5, 2024 06:45AM Merck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and Oncology Pipeline
Jan 3, 2024 06:45AM Merck to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Dec 22, 2023 08:01AM Merck (MRK) Reports Patritumab Deruxtecan Granted Priority Review in the U.S.
Dec 22, 2023 08:00AM Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Dec 20, 2023 04:30PM Merck (MRK) Receives CRL for Gefapixant
Dec 20, 2023 04:30PM Merck Provides U.S. Regulatory Update on Gefapixant
Dec 20, 2023 06:45AM Merck to Participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference
Dec 19, 2023 06:45AM Merck (MRK) Granted FDA Priority Review for V116
Dec 19, 2023 06:45AM FDA Grants Priority Review to Merck’s New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults
Dec 18, 2023 06:45AM Merck (MRK) Announces EU Approval of KEYTRUDA Plus Chemotherapy for New First-Line Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors Expressing PD-L1 (CPS ≥1) and Advance
Dec 18, 2023 06:45AM European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy for New First-Line Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors Expressing PD-L1 (C
Dec 15, 2023 05:00PM Merck (MRK) Announces FDA Approval of Expanded Indication for KEYTRUDA Plus Padcev for the First-Line Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial Cancer
Dec 15, 2023 05:00PM FDA Approves Expanded Indication for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial Ca
Dec 15, 2023 03:34AM Merck (MRK) Announces FDA Approval of WELIREG
Dec 14, 2023 07:00PM FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI
Dec 13, 2023 04:55PM Merck Ranks No. 1 on Newsweek’s List of America’s Most Responsible Companies 2024
Dec 11, 2023 07:00AM Merck (MRK), Moderna (MRNA) initiate INTerpath-002 Phase 3 trial of V940/KEYTRUDA combo in NSCLC
Dec 11, 2023 06:56AM Merck (MRK) announces positive CVMP opinion on BRAVECTO for dogs
Dec 11, 2023 06:45AM Merck Animal Health Receives Positive CVMP Opinion for an Injectable Formulation of BRAVECTO® (Fluralaner) for Use in Dogs
Dec 11, 2023 06:45AM Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected N
Dec 8, 2023 06:45AM Merck and Eisai Provide Update on Phase 3 LEAP-001 Trial Evaluating (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma
Dec 7, 2023 06:51AM Merck (MRK) stops Phase 3 KEYLYNK-008 KEYTRUDA trial in NSCLC after it did not not demonstrate improvement in overall survival
Dec 7, 2023 06:45AM Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LYNPARZA® (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility
Dec 7, 2023 06:06AM Merck (MRK) phase 2 KeyVibe-002 trial extended survival but did not reach statistical significance
Dec 7, 2023 06:00AM Merck Announces Findings from Phase 2 KeyVibe-002 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab in Previously Treated Patients with Metastatic Non-Small Cell Lung
Nov 30, 2023 05:00PM FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic
Nov 28, 2023 01:17PM Merck Announces First-Quarter 2024 Dividend
Nov 28, 2023 06:48AM Merck (MRK) STRIDE-3 Trial of V116 Vaccine Demonstrated Superior Immunogenicity vs PCV20 in Older Adults
Nov 28, 2023 06:45AM Merck’s V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV
Nov 21, 2023 06:45AM Merck (MRK) to Acquire Caraway Therapeutics for Up to $610M
Nov 21, 2023 06:45AM Merck to Acquire Caraway Therapeutics, Inc.
View More Recent Stories View Older Stories